Kymera Therapeutics KYMR

$ 40.17 2.62%

Quarterly report 2024-Q3
added 10-31-2024

Kymera Therapeutics Balance Sheet 2011-2024 | KYMR

Annual Balance Sheet Kymera Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-104 M	-64.6 M	-44.4 M	-	-54.8 M	-40.6 M	-	-	-	-	-	-	-
Long Term Debt	1.3 M	1.25 M	1.14 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	5.07 M	2.54 M	2.46 M	2.57 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	157 M	74 M	-	-	-	-	-	-	-
Total Current Liabilities	85.7 M	71.3 M	92.5 M	111 M	-	-	-	-	-	-	-	-	-
Total Liabilities	181 M	113 M	146 M	203 M	191 M	78.7 M	-	-	-	-	-	-	-
Deferred Revenue	37.9 M	35.3 M	61.7 M	92.6 M	23.3 M	-	-	-	-	-	-	-	-
Retained Earnings	-531 M	-384 M	-229 M	-129 M	-76.5 M	-35.2 M	-	-	-	-	-	-	-
Total Assets	576 M	603 M	606 M	487 M	117 M	44.2 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	110 M	68.4 M	48 M	31 M	76 M	-	-	-	-	-	-	-	-
Book Value	395 M	490 M	460 M	284 M	-74.4 M	-34.4 M	-	-	-	-	-	-	-
Total Shareholders Equity	395 M	490 M	460 M	284 M	-74.4 M	-34.4 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Kymera Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	1.74 M	943 K	1.16 M	1.3 M	643 K	762 K	989 K	1.25 M	690 K	927 K	927 K	1.14 M	1.35 M	1.14 M	498 K	604 K	604 K	604 K	604 K	1.16 M	1.16 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	142 M	141 M	157 M	181 M	157 M	147 M	152 M	113 M	126 M	125 M	134 M	146 M	159 M	176 M	189 M	203 M	203 M	203 M	203 M	82 M	82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	20 M	19.3 M	22.6 M	37.9 M	27.4 M	24.3 M	32.2 M	35.3 M	55.8 M	59.5 M	60.9 M	61.7 M	66.2 M	82.3 M	87.9 M	92.6 M	92.6 M	92.6 M	92.6 M	23.3 M	23.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-684 M	-621 M	-579 M	-531 M	-516 M	-464 M	-425 M	-384 M	-349 M	-306 M	-266 M	-229 M	-195 M	-166 M	-142 M	-129 M	-129 M	-129 M	-129 M	-76.5 M	-76.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	1.03 B	826 M	868 M	576 M	552 M	582 M	614 M	603 M	638 M	523 M	563 M	606 M	642 M	434 M	465 M	487 M	487 M	487 M	487 M	117 M	117 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	111 M	67.6 M	93.5 M	110 M	81.1 M	52.4 M	50.2 M	68.4 M	156 M	76.9 M	33.7 M	48 M	157 M	84.9 M	53.1 M	31 M	31 M	31 M	31 M	76 M	76 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	893 M	685 M	711 M	395 M	396 M	435 M	462 M	490 M	513 M	398 M	429 M	460 M	483 M	258 M	275 M	284 M	284 M	284 M	284 M	34.7 M	34.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	893 M	685 M	711 M	395 M	396 M	435 M	462 M	490 M	513 M	398 M	429 M	460 M	483 M	258 M	275 M	284 M	284 M	284 M	284 M	-74.4 M	-74.4 M	-52.1 M	-	-34.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency